How should sinus bradycardia be managed pre‑operatively in a patient taking beta‑blockers?

Pre-operative Management of Sinus Bradycardia on Beta Blocker

Continue the beta blocker through the perioperative period at the current stable dose, using clinical judgment to titrate based on hemodynamics, as acute discontinuation is harmful and increases mortality risk. 1

Core Management Principle

The 2024 AHA/ACC/ACS perioperative guideline provides a Class I recommendation (Level B-NR) that patients on stable doses of beta blockers undergoing noncardiac surgery should continue beta blockers through the perioperative period as appropriate based on clinical circumstances 1. This recommendation is rooted in evidence showing that acute withdrawal of beta blockers in patients on long-term therapy is harmful and may have contributed to adverse outcomes in early studies.

Key Clinical Considerations

When Beta Blocker Continuation is Appropriate

• Patient has a clear long-term indication for beta blockade (heart failure, coronary artery disease, hypertension, arrhythmia control) 1
• Stable dosing regimen established prior to surgery
• The sinus bradycardia is asymptomatic or minimally symptomatic

Addressing the Bradycardia Itself

The 2018 ACC/AHA/HRS bradycardia guideline emphasizes that reversible causes of sinus bradycardia should be addressed first (Class I, Level C-EO) 2. However, this applies when the beta blocker can be safely discontinued or reduced. In the perioperative setting, this creates a clinical tension that must be resolved by:

1. Assessing symptomatology: If the patient has symptomatic bradycardia (syncope, lightheadedness, significant fatigue), the beta blocker indication must be weighed against bradycardia risk 2

2. Evaluating beta blocker necessity:

   • If used solely for hypertension control, consider switching to agents without negative chronotropic effects (ACE inhibitors, ARBs, diuretics) well before surgery 2
   • If used for heart failure, CAD, or arrhythmia control, continuation is typically mandatory 1

3. Dose titration strategy: The guidelines explicitly state to use clinical judgment to titrate beta blockers appropriately during the perioperative period based on hemodynamics 1

Practical Perioperative Algorithm

Pre-operative Assessment (Ideally >7 Days Before Surgery)

• Document baseline heart rate and blood pressure on current beta blocker dose
• Verify the indication for beta blockade is compelling (not just hypertension alone)
• Assess for symptoms of bradycardia: syncope, presyncope, fatigue, dyspnea
• Check for other negative chronotropic medications (calcium channel blockers, digoxin, antiarrhythmics) that may compound bradycardia risk 2, 3

If Bradycardia is Asymptomatic

• Continue beta blocker at current dose through surgery 1
• Ensure anesthesia team is aware of baseline bradycardia and beta blocker use
• Plan for intraoperative management with short-acting agents (atropine, glycopyrrolate, isoproterenol) available 4
• No permanent pacing indicated for asymptomatic bradycardia 2

If Bradycardia is Symptomatic

• Do not abruptly discontinue the beta blocker 1
• Consider dose reduction if surgery can be delayed to allow titration 2
• Evaluate for alternative agents if indication permits (e.g., switch from propranolol to pindolol, which causes less sinus node depression) 5
• Temporary pacing may be considered for severe symptomatic bradycardia, though guidelines suggest addressing reversible causes first 2

Critical Pitfalls to Avoid

Do NOT Discontinue Beta Blockers Acutely

Early studies suggesting beta blocker benefit may have actually demonstrated harm from withdrawal 1. Acute discontinuation increases perioperative mortality and cardiovascular events. The focus must be on ensuring continuation through hospital stay and at discharge unless clear contraindications arise 1.

Do NOT Initiate Beta Blockers on Day of Surgery

The POISE trial demonstrated that initiating beta blockers on the day of surgery, particularly at higher doses, increases postoperative mortality (Class III Harm recommendation, Level B-R) 1. This is relevant if considering beta blocker initiation for rate control of the bradycardia itself—which would be counterproductive.

Recognize Drug Interactions

Beta blockers combined with non-dihydropyridine calcium channel blockers (diltiazem, verapamil) can cause profound sinus bradycardia and sinus arrest with more than additive effects 3. Review the complete medication list for compounding negative chronotropic agents.

Intraoperative Considerations

• Anticipate exaggerated bradycardia during anesthetic induction, particularly with vagal stimulation 4
• Have short-acting chronotropic agents immediately available (atropine 0.5-1 mg IV, glycopyrrolate 0.2-0.4 mg IV)
• Consider isoproterenol infusion (0.01 µg/kg/min) for refractory bradycardia 4
• Avoid high-dose neuraxial anesthesia that may compound bradycardia through sympathetic blockade

Post-operative Management

• Resume beta blocker as soon as oral intake tolerated 1
• Monitor for hemodynamic stability with continued beta blockade
• Ensure discharge prescription includes beta blocker at appropriate dose 1
• Document clear indication for continued therapy in discharge summary

Special Circumstance: When Beta Blocker Must Be Reduced or Stopped

If the beta blocker indication is weak (e.g., mild hypertension alone) and symptomatic bradycardia is present:

• Taper gradually over ≥7 days before surgery if possible 1
• Switch to alternative antihypertensive without chronotropic effects 2
• Close hemodynamic monitoring during taper for rebound hypertension or tachycardia
• This scenario should be rare—most patients on beta blockers have compelling indications requiring continuation

Evidence Quality Note

The perioperative beta blocker recommendations are based on moderate to high quality evidence from large RCTs including POISE, which enrolled over 8,000 patients 1, 6. The bradycardia guideline recommendations for reversible causes are expert opinion (Level C-EO) but represent consensus 2. The strongest evidence supports continuation of established beta blocker therapy rather than initiation or discontinuation in the perioperative period.